Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma
Yuqin Song, Huilai Zhang, Huiqiang Huang, Qingyuan Zhang, Hongmei Jing, Chao Wang, Wu Chun, Dong-Hang Li, Yu Dai, Kathryn Humphrey, Jun Zhu
Abstract
Not available.
Topics & Concepts
Refractory (planetary science)Diffuse large B-cell lymphomaMedicineLymphomaInternal medicineOncologyCancer researchMaterials scienceComposite materialLymphoma Diagnosis and TreatmentCAR-T cell therapy researchChronic Lymphocytic Leukemia Research